Clinical Trial Update: Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on Lipiodol-TACE with idarubicin for hepatocellular carcinoma across Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lipiodol-TACE with idarubicin (idarubicin)

Snippet

Sponsor: Zhongda Hospital | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: UNKNOWN